Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478542 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD11B1LTA4HKDM4EALDH1A1 | |
| SCHEMBL14971485 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD11B1LTA4H | |
| SCHEMBL14971483 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD11B1LTA4H | |
| SCHEMBL4550212 | 0.83 | DRD2 (0.42) | SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL3476998 | 0.81 | HSD11B1 (0.55) | SMN1; SMN2HSD11B1HRH3 | |
| SCHEMBL13212683 | 0.80 | LTA4H (0.36) | LTA4H | |
| SCHEMBL20541135 | 0.78 | SLC18A3 (0.42) | LTA4HKDM4EALDH1A1 | |
| SCHEMBL3477460 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2HSD11B1EPHX1EPHX2HRH3 | |
| SCHEMBL17946924 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD11B1HRH3KDM4E | |
| SCHEMBL8226927 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2HSD11B1HRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164237-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164236-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164235-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164233-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3643717-B1 | 7-SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-06-02 | — | — | EP | disclosed |
| EP-3053926-B1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-9656996-B2 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| EP-3059238-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2016-08-24 | — | — | EP | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013074518-A1 | MODULATING CERTAIN TYROSINE KINASES | TESARO, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8440651-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8158625-B2 | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | HOFFMAN-LA ROCHE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 3309/4885HSD11B1 766/4885LTA4H 1303/4885 |
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3R5 | SMN1; SMN2 4592/4885HSD11B1 78/4885LTA4H 2260/4885 |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PI4K2B, PIK3CA, PIK3R2 | SMN1; SMN2 3259/4885HSD11B1 321/4885LTA4H 2269/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | SMN1; SMN2 4299/4885HSD11B1 1590/4885LTA4H 3681/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | SMN1; SMN2 2248/4885HSD11B1 690/4885LTA4H 2801/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 3309/4885HSD11B1 766/4885LTA4H 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.